Bank of New York Mellon’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $513K | Buy |
146,556
+6,786
| +5% | +$25.7K | ﹤0.01% | 3741 |
|
|
2026
Q1 | $540K | Buy |
139,770
+438
| +0.3% | +$1.72K | ﹤0.01% | 3565 |
|
|
2025
Q4 | $548K | Sell |
139,332
-54,083
| -28% | -$239K | ﹤0.01% | 3558 |
|
|
2025
Q3 | $903K | Buy |
193,415
+4,759
| +3% | +$17.2K | ﹤0.01% | 3266 |
|
|
2025
Q2 | $587K | Sell |
188,656
-861
| -0.5% | -$2.78K | ﹤0.01% | 3420 |
|
|
2025
Q1 | $641K | Sell |
189,517
-3,798
| -2% | -$17.7K | ﹤0.01% | 3323 |
|
|
2024
Q4 | $1.1M | Sell |
193,315
-56,213
| -23% | -$362K | ﹤0.01% | 3102 |
|
|
2024
Q3 | $1.46M | Sell |
249,528
-44,892
| -15% | -$326K | ﹤0.01% | 2916 |
|
|
2024
Q2 | $2.33M | Buy |
294,420
+44,289
| +18% | +$371K | ﹤0.01% | 2712 |
|
|
2024
Q1 | $2.33M | Sell |
250,131
-2,776
| -1% | -$23.4K | ﹤0.01% | 2691 |
|
|
2023
Q4 | $2.13M | Buy |
252,907
+60,038
| +31% | +$436K | ﹤0.01% | 2802 |
|
|
2023
Q3 | $1.49M | Buy |
192,869
+1,455
| +0.8% | +$13.3K | ﹤0.01% | 2960 |
|
|
2023
Q2 | $2.19M | Buy |
191,414
+92,926
| +94% | +$961K | ﹤0.01% | 2783 |
|
|
2023
Q1 | $759K | Hold |
98,488
| – | – | ﹤0.01% | 3263 |
|
|
2022
Q4 | $601K | Sell |
98,488
-229
| -0.2% | -$1.3K | ﹤0.01% | 3462 |
|
|
2022
Q3 | $584K | Hold |
98,717
| – | – | ﹤0.01% | 3491 |
|
|
2022
Q2 | $584K | Buy |
98,717
+56,116
| +132% | +$379K | ﹤0.01% | 3494 |
|
|
2022
Q1 | $325K | Hold |
42,601
| – | – | ﹤0.01% | 3972 |
|
|
2021
Q4 | $115K | Sell |
42,601
-45,786
| -52% | -$156K | ﹤0.01% | 4384 |
|
|
2021
Q3 | $232K | Sell |
88,387
-2,869
| -3% | -$9.32K | ﹤0.01% | 4143 |
|
|
2021
Q2 | $377K | Sell |
91,256
-85,334
| -48% | -$387K | ﹤0.01% | 3897 |
|
|
2021
Q1 | $831K | Sell |
176,590
-1,637
| -0.9% | -$11.2K | ﹤0.01% | 3438 |
|
|
2020
Q4 | $1.27M | Sell |
178,227
-963,999
| -84% | -$9.27M | ﹤0.01% | 3120 |
|
|
2020
Q3 | $12.2M | Buy |
1,142,226
+19,791
| +2% | +$232K | ﹤0.01% | 1744 |
|
|
2020
Q2 | $14.2M | Buy |
1,122,435
+224,246
| +25% | +$2.61M | ﹤0.01% | 1644 |
|
|
2020
Q1 | $8.22M | Buy |
898,189
+340,650
| +61% | +$3.91M | ﹤0.01% | 1808 |
|
|
2019
Q4 | $7.78M | Buy |
557,539
+457,473
| +457% | +$6.65M | ﹤0.01% | 2117 |
|
|
2019
Q3 | $1.72M | Buy |
100,066
+206
| +0.2% | +$4.33K | ﹤0.01% | 2830 |
|
|
2019
Q2 | $2.72M | Buy |
99,860
+10,462
| +12% | +$239K | ﹤0.01% | 2641 |
|
|
2019
Q1 | $1.71M | Buy |
89,398
+939
| +1% | +$12.2K | ﹤0.01% | 2856 |
|
|
2018
Q4 | $831K | Buy |
88,459
+3,543
| +4% | +$45.5K | ﹤0.01% | 3214 |
|
|
2018
Q3 | $1.61M | Buy |
84,916
+1,206
| +1% | +$23.1K | ﹤0.01% | 2984 |
|
|
2018
Q2 | $1.64M | Buy |
83,710
+171
| +0.2% | +$3.38K | ﹤0.01% | 2974 |
|
|
2018
Q1 | $1.57M | Buy |
83,539
+5,793
| +7% | +$125K | ﹤0.01% | 2948 |
|
|
2017
Q4 | $1.29M | Buy |
77,746
+15,888
| +26% | +$272K | ﹤0.01% | 3100 |
|
|
2017
Q3 | $1.27M | Buy |
61,858
+8,633
| +16% | +$97.4K | ﹤0.01% | 3096 |
|
|
2017
Q2 | $477K | Buy |
53,225
+9,207
| +21% | +$92.7K | ﹤0.01% | 3623 |
|
|
2017
Q1 | $582K | Buy |
44,018
+5,952
| +16% | +$72.2K | ﹤0.01% | 3498 |
|
|
2016
Q4 | $485K | Buy |
38,066
+4,701
| +14% | +$60.4K | ﹤0.01% | 3605 |
|
|
2016
Q3 | $401K | Buy |
33,365
+90
| +0.3% | +$1.22K | ﹤0.01% | 3638 |
|
|
2016
Q2 | $365K | Buy |
33,275
+9,803
| +42% | +$120K | ﹤0.01% | 3659 |
|
|
2016
Q1 | $205K | Buy |
23,472
+9,481
| +68% | +$108K | ﹤0.01% | 3781 |
|
|
2015
Q4 | $307K | Buy |
+13,991
| New | +$322K | ﹤0.01% | 3716 |
|
Other funds holding VYGR
AC
VPC
OM
Bank of New York Mellon's VYGR Position: Q2 2026 in Review
Bank of New York Mellon increased its Voyager Therapeutics (VYGR) stake by 4.9% in Q2 2026, buying an estimated $25.7K and bringing the position to 146,556 shares worth $513K. The position accounts for ﹤0.01% of the portfolio, ranked #3741.
Bank of New York Mellon first reported a position in VYGR in Q4 2015 and has held it in 43 quarters since. The position peaked at $14.2M in Q2 2020. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Bank of New York Mellon held 146,556 shares of Voyager Therapeutics worth $513K as of Q2 2026.
- Bank of New York Mellon bought 6,786 Voyager Therapeutics shares in Q2 2026, an estimated $25.7K.
- Voyager Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3741 holding.
- Bank of New York Mellon first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 43 quarters since.
- Bank of New York Mellon's Voyager Therapeutics position peaked at $14.2M in Q2 2020.
- 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.